PRANA Biotechnology Completes Final Patient Dosing in Phase IIa Trial of PBT2 in Alzheimer’s Disease Patients

MELBOURNE, AUSTRALIA--(Marketwire - December 18, 2007) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced it has completed final patient dosing in its Phase IIa clinical trial of PBT2 in patients with early Alzheimer’s disease.

MORE ON THIS TOPIC